11 results about "Decreased cholesterol" patented technology

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The invention relates to the technical field of probiotics and application thereof, in particular to a plant lactobacillus ZKAW02 strain, a fungicide and application of the fungicide. The invention relates to a plant lactobacillus ZKAW02 strain, which is classified and named as plant lactobacillus, the plant lactobacillus ZKAW02 strain is preserved in Guangdong Province Microbial Culture Collection Center on September 27, 2024, and the preservation number is GDMCC No: 65219. The invention further discloses a preparation method of the plant lactobacillus ZKAW02 strain. The plant lactobacillus ZKAW02 strain has the advantages that the plant lactobacillus ZKAW02 strain is named as plant lactobacillus, and the plant lactobacillus ZKAW02 strain is preserved in Guangdong Province Microbial Culture Collection Center on September 27, 2024. The lactobacillus plantarum ZKAW02 has the effects of remarkably reducing the cholesterol level, remarkably regulating the blood fat level of the liver and excrement and remarkably increasing the short-chain fatty acid level in the excrement of a high-fat rat, so that the expression level of lipid metabolism related signal channel genes is regulated, the intestinal flora homeostasis is regulated, the liver tissue damage is repaired, and the anti-tumor effect is achieved. The effects of regulating lipid metabolism and intestinal health are achieved.

The invention discloses a strain of lactobacillus plantarum SMU-KDLP2312 and application thereof, the strain of lactobacillus plantarum SMU-KDLP2312 is classified and named as Lactobacillus plantarum, the strain of lactobacillus plantarum SMU-KDLP2312 is named as Lactobacillus plantarum, and the strain of lactobacillus plantarum SMU-KDLP2312 is named as Lactobacillus plantarum. The strain is preserved in Guangdong Microbial Culture Collection Center on March 21, 2025, with the preservation number of GDMCC No.66040. The strain is preserved in the Guangdong Microbial Culture Collection Center. The lactobacillus plantarum SMU-KDLP2312 system is obtained by being separated and screened from intestinal tracts of Tibetan sheep, and has relatively strong stress resistance and in-vitro antibacterial ability. Meanwhile, the lactobacillus plantarum SMU-KDLP2312 has a relatively high survival rate in an acid environment, has relatively good tolerance to bile salt, has the effect of reducing cholesterol, and has the potential of becoming a good probiotic effect regulator. As one of feed additive strains, when applied to daily ration, the strain can promote the growth performance of Tibetan sheep to a certain extent, adjust the balance of animal intestinal flora and enhance the proliferation of beneficial bacteria.

The present invention relates to use of a GLP-1R / GLP-2R dual agonist, namely dapiglutide, for reducing cholesterol, in particular total cholesterol (TC) and low-density lipoprotein cholesterol (LDL cholesterol). The invention also relates to dapiglutide for treatment of hyperlipidaemia, in particular hypercholesterolaemia.

The invention provides a blood fat-reducing ganoderma lucidum spore powder pharmaceutical composition as well as a preparation method and application thereof, and belongs to the technical field of medicines. Comprising a ganoderma lucidum spore powder extract and a pharmaceutical composition, and the mass ratio of the ganoderma lucidum spore powder extract to the pharmaceutical composition is 10: (1-2); the pharmaceutical composition contains a simvastatin derivative and an apatamuron derivative. The prepared blood-fat-reducing ganoderma lucidum spore powder pharmaceutical composition adopts a mixed preparation of traditional Chinese medicine components and western medicine components, has complementary advantages, can quickly reduce cholesterol content and take effect quickly on one hand, can fundamentally inhibit cholesterol synthesis and improve metabolic disorder of hyperlipidemia on the other hand, and is small in side effect, high in patient compliance, good in effect and free of toxic and side effects on the other hand. Certain anti-inflammatory, anti-thrombotic and anti-tumor effects and the like are achieved, and the application prospect is wide.

The invention relates to the technical field of microorganisms, and discloses a strain of lactobacillus plantarum HR65, the preservation number of which is CGMCC (China General Microbiological Culture Collection Center) No.35607. The invention also discloses a preparation method of the lactobacillus plantarum HR65. The strain can be used for fermenting various carbohydrate compounds to grow, has obvious effects in the aspects of removing peculiar smell of traditional Chinese medicines and improving flavor, and particularly can be used for reducing the contents of 1, 3, 5-trithiane, 3-phenyl-2-acrolein and other bad flavor substances in the spleen-nourishing powder. The fermented spleen-nourishing powder and the purslane can obviously improve the contents of organic acids such as lactic acid, 2-hydroxy-3-methylbutyric acid and the like and polypeptides; the fermented spleen-nourishing powder can also improve the levels of short-chain fatty acids such as acetic acid and butyric acid. The strain has the characteristics of bacteriostasis, oxidation resistance, production of SOD enzyme, cholesterol reduction, self-agglutination and hydrophobicity, can be widely used for fermenting matrixes such as carrots, rosa roxburghii tratt, various fruits, Chinese herbal medicines, cereals and milk, improves the flavor and quality of the matrixes, and has good application value in plant-based fermentation products, traditional Chinese medicine flavor improvement, functional food and probiotic preparation development.

This application relates to compounds such as compounds of Formula (I) that block SREBP2-induced hepatic PCSK9 expression, compositions comprising these compounds and methods of use thereof; for example, for treating diseases, disorders or conditions treatable by blocking SREBP2 activation and / or PCSK9 gene expression.

The invention provides a composition beneficial to maintaining the healthy level of blood fat and application of the composition. Specifically, the composition provided by the invention comprises phytosterol ester, fish oil and beta-glucan, and the weight ratio of the phytosterol ester to the fish oil to the beta-glucan is 1: (1-5): (10-100). The composition disclosed by the invention can be beneficial to maintaining the healthy level of blood fat, reducing / preventing low-density cholesterol accumulation and reducing the cholesterol level.

The invention relates to the technical field related to biological medicine, in particular to a method for inhibiting cholesterol esterification of macrophages, through targeted regulation of a PPAR-gamma / LXR-alpha signal channel by means of palmatine (PAL), foam cell formation can be effectively reduced, and accordingly atherosclerosis (AS) can be improved. Oxidized low-density lipoprotein (ox-LDL) is used for inducing foaming, then 25-100 [mu] g / ml palmatine is used for intervening for 48 hours, and experiments show that the palmatine remarkably reduces the cholesterol esterification rate (from 52.17% to 41.88%, Plt; according to the present invention, with the application of the palmatine in the preparation of the medicine, the expression of cholesterol efflux genes such as ABCA1, ABCG1 and the like is up-regulated, the release of inflammatory factors IL-6 and TNF-alpha is inhibited (reduced by more than 60%), and the molecular docking proves that the combination of the palmatine and the PPAR-V is stable (the combination energy is-8.482 kcal / mol), and is superior to the traditional medicine; the invention provides a new strategy for natural, safe and multi-target intervention of AS, and has significant clinical application potential.

The invention provides oral cyclodextrin inclusion complex formulations in which inclusion complexes of camphene from the camphene CD inclusion complex; borneol from the borneol CD inclusion complex; geraniol from the geraniol CD inclusion complex; and, anethole from the anethole CD inclusion complex are provided together with an enzyme having a cyclodextrin-degrading activity capable of digesting cyclodextrins, so that upon delivery of the formulation to a target tissue the CD-degrading enzyme is activated and releases the camphene from the camphene CD inclusion complex; borneol from the borneol CD inclusion complex; geraniol from the geraniol CD inclusion complex; and, anethole from the anethole CD inclusion complex from the cyclodextrins. These cyclodextrin inclusion complex formulations may be used for lowering cholesterol, triglycerides and / or LDL levels.

This invention belongs to the field of microbial technology and discloses a strain of *Lactobacillus facultativeus* TA15 and its application in the fermentation preparation of red sour soup. The strain is *Lactobacillus facultativeus* (TA15). Levilactobacillus zymae TA15 was deposited at the Guangdong Provincial Microbial Culture Collection Center (GDMCC) on May 19, 2025, with accession number GDMCC No. 66351. This strain has a strong acid-producing capacity, effectively reducing cholesterol and triglyceride levels. It also possesses excellent acid and bile salt resistance, cell surface characteristics, and antibacterial properties, meeting food-grade safety requirements. Its application in the fermentation of red sour soup effectively increases the product's acidity and shortens the fermentation cycle. The total acid content of the resulting fermented product reaches 15.75 g / kg, demonstrating promising application prospects in the functional food field.